Fulcrum Therapeutics, Inc. FULC
Set alert
3.73 USD +0.08 +2.19%
As of Nov 3, 11:35 AM ET
3.69 Day range 3.75
2.83 52-week range 15.74
- YTD
- -67.02%
- 1 year
- -58.65%
- Open
- 3.69
- Prev close
- 3.65
- Mkt cap
- 284.90M
- Vol
- 395.12K
- Avg vol
- 1.52M
- EPS
- -1.21
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.69
- High
- 3.75
- Forward P/E
- -3.84
- Beta
- 2.23
- Short ratio
- 7.67
- Inst. own
- 89.70%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jul 31, 2024
- 50-d avg
- 3.58
- 200-d avg
- 6.57
- 1y target
- 5.29
Analyst view
Price target (mean) 5.29 +41.7% upside
Now 3.73
- Target (low)
- 2.00
- Target (mean)
- 5.29
- Target (high)
- 14.00
Ratings (0m) 8 2 buy · 5 hold · 1 sell
- Strong buy1
- Buy1
- Hold5
- Sell0
- Strong sell1
Recommendation trend
- This month 8
- 1 month ago 8
- 2 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.28714 | -0.34 – -0.23 | -0.40 | +28.2% | 0 | -100.0% | 7 |
| Next quarter | -0.2625 | -0.30 – -0.22 | -0.43 | +39.0% | 0 | 0.0% | 4 |
| Current year | -0.14833 | -0.24 – -0.08 | -1.59 | +90.7% | 80.40M | +2766.5% | 6 |
| Next year | -1.05 | -1.51 – -0.81 | -0.14833 | -609.8% | 0 | -100.0% | 7 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | RBC Capital | Reiterated | Sector Perform | Sector Perform |
| Nov 14, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Sep 13, 2024 | RBC Capital | Downgrade | Outperform | Sector Perform |
| Sep 13, 2024 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Sep 12, 2024 | Leerink Partners | Downgrade | Outperform | Market Perform |
| Sep 12, 2024 | B of A Securities | Downgrade | Neutral | Underperform |
| Sep 12, 2024 | Stifel | Downgrade | Buy | Hold |
| Sep 12, 2024 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
| Sep 9, 2024 | B of A Securities | Upgrade | Underperform | Neutral |
| Aug 1, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 10, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| May 20, 2024 | Cantor Fitzgerald | Initiated | — | Overweight |
| May 14, 2024 | Goldman Sachs | Upgrade | Neutral | Buy |
| May 14, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 14, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| May 13, 2024 | Goldman Sachs | Upgrade | Neutral | Buy |
| Mar 13, 2024 | RBC Capital | Initiated | — | Outperform |
| Feb 28, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 28, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Jan 26, 2024 | Goldman Sachs | Maintained | Neutral | Neutral |
| Jan 25, 2024 | Goldman Sachs | Maintained | Neutral | Neutral |
| Sep 25, 2023 | Goldman Sachs | Initiated | — | Neutral |
| Aug 23, 2023 | HC Wainwright & Co. | Upgrade | Neutral | Buy |
| Aug 22, 2023 | Oppenheimer | Reiterated | Outperform | Outperform |
| Aug 22, 2023 | Stifel | Upgrade | Hold | Buy |
| Aug 4, 2023 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| May 16, 2023 | Oppenheimer | Maintained | Outperform | Outperform |
| May 16, 2023 | HC Wainwright & Co. | Maintained | Neutral | Neutral |
| May 5, 2023 | Goldman Sachs | Maintained | — | Neutral |
| May 4, 2023 | Goldman Sachs | Downgrade | Buy | Neutral |